Pardes Biosciences Inc. (PRDS)
NASDAQ: PRDS
· Real-Time Price · USD
2.18
0.02 (0.93%)
At close: Aug 30, 2023, 9:59 PM
Pardes Biosciences Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -84.61M | -102.06M | -102.03M | -90.18M | -65.19M | -45.09M | -28.2M | -13.89M | -12.67M | -4.53M |
Interest Income | 2.8M | 959K | 959K | 959K | 3K | 3K | 3K | 3K | n/a | n/a |
Pretax Income | -76.14M | -93M | -96.63M | -86.76M | -74.94M | -55.44M | -38.52M | -24.17M | -12.66M | -4.52M |
Net Income | -70.58M | -87.15M | -94.42M | -84.54M | -74.64M | -55.44M | -38.52M | -24.17M | -12.66M | -4.52M |
Selling & General & Admin | 26.17M | 28.07M | 29.47M | 26.68M | 20.91M | 15.19M | 8.04M | 4.1M | 2.96M | 1.08M |
Research & Development | 56.72M | 70.13M | 70.35M | 61.28M | 51.98M | 37.91M | 28.15M | 17.79M | 9.71M | 3.44M |
Other Expenses | n/a | n/a | -15K | -15K | -15K | -11K | 7K | 7K | 7K | 3K |
Operating Expenses | 82.88M | 98.2M | 99.82M | 87.96M | 75.18M | 55.39M | 38.49M | 24.18M | 12.67M | 4.53M |
Interest Expense | 959K | 959K | 959K | 959K | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 82.88M | 98.2M | 99.82M | 87.96M | 75.18M | 55.39M | 38.49M | 24.18M | 12.67M | 4.53M |
Income Tax Expense | 20.14M | 19.84M | 23.48M | -2.22M | -298K | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 60.21M | 59.77M | 59.34M | 58.38M | 57.69M | 57.04M | 56.77M | 56.65M | 56.65M | 56.65M |
Shares Outstanding (Diluted) | 60.21M | 59.77M | 59.34M | 58.38M | 57.69M | 57.04M | 56.77M | 56.65M | 56.65M | 56.65M |
EPS (Basic) | -1.2 | -1.49 | -1.63 | -1.47 | -1.3 | -0.97 | -0.67 | -0.42 | -0.22 | -0.08 |
EPS (Diluted) | -1.2 | -1.49 | -1.63 | -1.47 | -1.3 | -0.97 | -0.67 | -0.42 | -0.22 | -0.08 |
EBITDA | -80.34M | -95.66M | -97.27M | -87.96M | -64.89M | -39.13M | -22.23M | -7.92M | -6.7M | -4.53M |
EBIT | -72.97M | -90.13M | -93.73M | -86.04M | -63.67M | -35.73M | -14.31M | n/a | n/a | n/a |
Depreciation & Amortization | -179K | 1.96M | 373.46K | 2.35M | 483.85K | 185.85K | 125.39K | 54K | n/a | n/a |